Royalty Pharma Plc
Statements
Segments
US companies must disclose in their mandatory reports how revenue breaks down across business segments, regions and product lines. We read that breakdown for you straight from the annual and quarterly reports (10-K and 10-Q) of Royalty Pharma Plc (RPRX). It shows which part of the business is growing — and which one is holding it back.
Revenue by product line
| Segment | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|
| Income from financial royalty assets | $1.96B 92.3% | $2.07B 90.2% · +5.4% | $2.13B 95.0% · +2.9% | $2.20B 93.3% · +3.4% | $2.15B 95.0% · -2.2% | $2.26B 95.1% · +5.2% |
| Other royalty income | $19.0M 0.9% | $53.1M 2.3% · +179.7% | $112.1M 5.0% · +111.0% | $156.8M 6.7% · +39.9% | $114.2M 5.0% · -27.2% | $117.0M 4.9% · +2.5% |
| Revenue from intangible royalty assets | $143.4M 6.8% | $171.2M 7.5% · +19.4% | – | – | – | – |
Large figure: segment revenue. Below it the share of revenue in that period and the change against the prior year.
Segment and region names are the ones the company itself uses and are shown as reported. Change and share refer to revenue.
Data as of: August 7, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q) · Segment figures: SEC EDGAR (10-K/10-Q reports)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.